Cipla Wins FDA Approval for Blood Pressure Generic

Indian drugmaker Cipla won the FDA’s approval to begin marketing a generic equivalent to Gilead’s near-blockbuster hypertension drug Letairis, Cipla officials announced.

Last week, Teva announced its own generic equivalent of Letairis (Amrbistentan), which is aimed at patients with pulmonary arterial hypertension.

Gilead earned $943 million from Letairis sales last year and nearly $887 million in 2017.